Nitric oxide: Therapeutic opportunities

Fundamental and Clinical Pharmacology

Volumn 17, Issue 1, 2003, Pages 1-10

  Vallance, Patrick ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biological mediator; Nitric oxide; Nitric oxide synthase

Indexed keywords

ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; VASODILATOR AGENT;

ANGIOPLASTY; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL DEATH; CELL GROWTH; DISEASE PREDISPOSITION; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GASTRITIS; HEADACHE; HUMAN; HYPERLIPIDEMIA; NEUROTRANSMISSION; NONHUMAN; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESTENOSIS; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SKIN INFECTION; SMOOTH MUSCLE RELAXATION; VASODILATATION;

ANIMALS; DRUG DESIGN; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III;

EID: 0037328993     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00124.x     Document Type: Review

References (78)

1. Hanafy K.A., Krumenacker J.S., Murad F. NO, nitrotyrosine and cyclic GMP in signal transduction. Med. Sci. Monit. (2001) 7 801-819.
2. Ignarro L.J. Physiology and pathophysiology of nitric oxide. Kidney Int. 55 (Suppl.) (1996) S2-S5.
3. Brown G.C. Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett. (1995) 369 136-139.
4. Stamler J.S., Lamas S., Fang F.C. Nitrosylation; the prototypic redox-based signaling mechanism. Cell (2001) 196 675-683.
5. Russwurm M., Koesling D. Isoforms of NO-sensitive guanylyl cyclase. Mol. Cell. Biochem. (2002) 230 159-164.
6. Huang E.P. Synaptic plasticity: a role for nitric oxide in LTP. Curr. Biol. (1997) 7 R141-R143.
7. Brown G.C. Regulation of mitochondrial respiration by nitrix oxide inhibition of cytochrome c oxidase. Biochim. Biophys. Acta (2001) 1504 46-57.
8. Gow A.J., Chen Q., Hess D.T., Day B.J., Ischiropoulos H., Stamler J.S. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J. Biol. Chem. (2002) 277 9637-9640.
9. Burney S., Caulfield J.L., Niles J.C., Wishnok J.S., Tannenbaum S.R. The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat. Res. (1999) 424 37-49.
10. Beckman J.S., Koppenol W.H. Nitrix oxide, superoxide and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. (1996) 271 C1424-C1437.
11. Hibbs J.B. Synthesis of nitric oxide from L-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. Res. Immunol. (1991) 142 565-569.
12. Furchgott R.F., Zawadski J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 288 373-376.
13. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) ii 997-1000.
14. Vallance P., Collier J., Moncada S. Nitric oxide synthesised from L-arginine mediates endothelium-dependent dilatation in human veins in vivo. Cardiovasc. Res. (1989) 23 1053-1057.
15. Barba G., Vallance P., Strazzulio P., MacAllister R. Effects of sodium intake on the pressor and renal responses to nitric oxide synthesis inhibition in normotensive individuals with different sodium sensitivity. J. Hypertens. (2000) 18 615-621.
16. Huang P.I., Lo E.H. Genetic analysis of NOS isoforms using nNOS and eNOS knockout animals. Prog. Brain Res. (1998) 118 13-25.
17. Radomski M.W., Zakar T., Salas E. Nitric oxide in platelets. Methods Enzymol. (1996) 269 88-107.
18. Chung H.T., Pae H.O., Choi B.M., Billiar T.R., Kim Y.M. Nitric oxide as a bioregulator of apoptosis. Biochem. Biophys. Res. Commun. (2001) 282 1075-1079.
19. Cayatte A.J., Palacino J.J., Horten K. Chronic inhibition of nitric oxide production accelerates enointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thromb. (1994) 14 753-759.
20. Naruse K., Shimizu K., Muramatsu M. et al. Long-term inhibition of NO synthesis promotes artherosclerosis in the hypercholesteroemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler. Thromb. (1994) 14 653-655.
21. Chen J., Kuhlencordt P.J., Astern J., Gyurko R., Huant P.L. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitrix oxide synthase double knockout mice. Circulation (2001) 104 2391-2394.
22. Huang Z., Huant P.L., Ma J. et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J. Cereb. Blood Flow Metab. (1996) 16 981-987.
23. Petros A., Lamb G., Leone A., Moncada S., Bennett D., Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. In: Moncada, Feelisch, Busse, Higgs (Eds), The biology of nitric oxide, 1995, pp. 458-462.
24. Vallance P., Chan N. Endothelial function and nitric oxide: clinical relevance. Heart (2001) 85 342-350.
25. Chan N., Colhoun H., Vallance P. Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. J. Am. Coll. Cardiol. (2001) 38 1814-1820.
26. Chan N., MacAllister R., Colhoun H., Vallance P., Hingorani A. Changes in endothelium-dependent vasodilatation and α-adrenergic responses in resistance vessels during the menstrual cycle in healthy women. J. Clin. Endocrinol. Metab. (2001) 86 2499-2504.
27. Hingorani A.D. Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000. Atherosclerosis (2001) 154 521-527.
28. Katusic Z.S. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am. J. Physiol. Heart. Circ. Physiol. (2001) 281 H981-H986.
29. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. (2000) 87 840-844.
30. O'Byrne S., Forte P., Roberts L.J. II et al. Diabetes (2000) 49 857-862.
31. Chan N.N., Vallance P., Colhoun H.M. Nitric oxide and vascular responses in Type I diabetes. Diabetologia (2000) 43 137-147.
32. Garthwaite J. Neural nitric oxide signalling. Trends Neurosci. (1995) 18 51-52.
33. Garthwaite J., Charles S.L., Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature (1988) 336 385-388.
34. Bennett M.R. The concept of long term potentiation of transmission at synapses. Prog. Neurobiol. (2000) 60 109-137.
35. Gammie S.C., Dawson V.L., Nelson R.J. Influence of nitric oxide on neuroendocrine function and behaviour. In: Ignarro L. (Ed.) Nitric oxide, biology and pathobiology, Academic Press. New York, 2000, pp. 429-438.
36. Schulz J.B., Matthews R.T., Klockgether T., Dichgans J., Beal M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. (1997) 174 193-197.
37. Rand M.J. Nitrergic transmission: nitric oxide as a mediator of non-adrenergic, non-cholinergic neuro-effector transmission. Clin. Exp. Pharmacol. Physiol. (1992) 19 147-169.
38. Gonzalez-Cadavid N.F., Ignarro L.J., Rajfer J. Nitric oxide and the cyclic GMP system in the penis. Mol. Urol. (1999) 3 51-59.
39. Kakuyama M., Ahluwalia A., Rodrigo J., Vallance P. Cholinergic contraction is altered in nNOS knockouts. Cooperative modulation of neural bronchoconstriction by nNOS and COX. Am. J. Respir. Crit. Care Med. (1999) 160 2072-2078.
40. Huang P.L., Dawson T.M., Bredt D.S., Snyder S.H., Fishman M.C. Targeted disruption of the neuronal nitric oxide synthase gene. Cell (1993) 75 1273-1286.
41. Lou Z.D., Cizkova D. The role of nitric oxide in nociception. Curr. Rev. Pain (2000) 4 459-466.
42. Lipton S.A. Neuronal protection and destruction by NO. Cell Death Differ. (1999) 6 943-951.
43. Vanderwinden J.M., Mailleux P., Schiffmann S.N., Vanderhaeghen J.J., De Laet M.H.N. Engl. J. Med. (1992) 327 511-515.
44. Chung E., Curtis D., Chen G. et al. Genetic evidence for the neuronal nitric oxide synthase gene (NOS1) as a susceptibility locus for infantile pyloric stenosis. Am. J. Hum. Genet. (1996) 58 363-370.
45. Holthusen H., Ding Z. Nitric oxide is not involved in vascular nociception of noxious physical stimuli in humans. Neurosci. Lett. (1997) 227 111-114.
46. Green S.J., Meltzer M.S., Hibbs J.B. Jr., Nacy C.A. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J. Immunol. (1990) 144 278-283.
47. Palmer R.M., Hickery M.S., Charles I.G., Moncada S., Bayliss M.T. Induction of nitric oxide synthase in human chondrocytes. Biochem. Biophys. Res. Commun. (1993) 193 398-405.
48. Davis K.L., Martin E., Turko I.V., Murad F. Novel effects of nitric oxide. Annu. Rev. Pharmacol. Toxicol. (2001) 41 204-236.
49. Vallance P., Charles I. Nitric oxide as an antimicrobial agent: does NO always mean NO? Gut (1998) 42 313-314.
50. Martasek P., Miller R.T., Roman L.J., Shea T., Masters B.S. Assay of isoforms of Escherichia coli-expressed nitric oxide synthase. Methods Enzymol. (1999) 301 70-78.
51. Petros A., Leone A., Moncada S., Bennett D., Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res. (1994) 28 34-39.
52. Rees D.D. Role of nitric oxide in the vascular dysfunction of septic shock. Biochem. Soc. Trans. (1995) 23 1025-1029.
53. Vallance P., Moncada S. The role of endogenous nitric oxide in human septic shock. New Horiz. (1993) 1 77-86.
54. Kuhlencordt P.J., Chen J., Han F., Astern J., Huang P.L. of inducible nitric oxide synthase reduce atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation (2001) 103 3099-3104.
55. Dijkstra G., Moshage H., van Dullemen H.M. et al. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J. Pathol. (1998) 186 416-421.
56. Wei X.Q., Charles I.G., Smith A. et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 375 408-411.
57. MacMicking I.D., Nathan C., Hom G. et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell (1995) 81 641-650.
58. Vallance P., Charles I. Nitric oxide in sepsis: of mice and men. Sepsis (1998) 1 93-100.
59. Mock B.A., Krall M.M., Byrd L.G. The inducible form of nitric oxide synthase (NOS2) isolated from murine macrophages maps near the nude mutation of mouse chromosome II. Eur. J. Immunogenet. (1994) 21 231-238.
60. Xu W., Charles I.G., Moncada S. Mapping of the genes encoding human inducible and endothelial nitric oxide synthase (NOS2 and NOS3) to the pericentric region of chromosome 17 and to chromosome 7, respectively. Genomics (1994) 21 419-422.
61. Annane D., Sanquer S., Sebille V. et al. Compartmentalised inducible nitric-oxide synthase activity in septic shock. Lancet (2000) 355 1143-1148.
62. Barnes P.J. Nitric oxide and airway disease. Ann Med (1995) 27 389-393.
63. Bruch-Gerharz D., Ruzicka T., Kolb-Bachofen V. Nitric oxide and its implications in skin homeostasis and disease - a review. Arch. Dermatol. Res. (1998) 290 643-651.
64. Kun J.F., Mordmuller B., Perkins D.J. et al. Nitric oxide synthase 2 (Lambarene) (G-954C), increased nitric oxide production, and protection against malaria. J. Infect. Dis. (2001) 184 330-336.
65. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J. Hypertens. (1992) 10 1025-1031.
66. De Belder A.J., MacAllister R., Radomski M.W., Moncada S., Vallance P. Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc. Res. (1994) 28 691-694.
67. Kaposzta Z., Baskerville P.A., Madge D., Fraser S., Martin J.F., Markus H.S. L-arginine and S-nitrosoglutathione reduce embolization in humans. Circulation (2001) 103 2371-2375.
68. Burgaud J.L., Riffaud J.P., Del Soldato P. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr. Pharm. Des. (2002) 8 201-213.
69. Steudd W., Hurford W.E., Zapol W.M. Inhaled nitric oxide: basic biology and clinical applications. Anaesthesiology (1999) 91 1090-1121.
70. Hardwick J.B., Tucker A.T., Wilks M., Johnston A., Benjamin N. A novel method for the delivery of nitric oxide therapy to the skin of human subjects using a semi-permeable membrane. Clin. Sci. (2001) 100 395-400.
71. Chuang A.T., Strauss J.D., Murphy R.A., Steers W.D. Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J. Urol. (1998) 160 257-261.
72. Barouch L.A., Harrison R.W., Skaf M.W. et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature (2002) 416 337-339.
73. Sarkar D., Vallance P., Amirmansour C., Harding S.E. Positive inotropic effects of NO donors in isolated guinea-pig and human cardiomyocytes independent of NO species and cyclic nucleotides. Cardiovasc. Res. (2000) 48 430-439.
74. Ashina M., Lassen L.H., Bendtsen L., Jensen R., Olesen J. Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial. Lancet (1999) 353 287-289.
75. Leiper J., Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. (1999) 43 542-548.
76. Murray-Rust J., Leiper J., McAlister M. et al. Crystal structure of dimethylarginine dimethylaminohydrolase (DDAH): insights into the hydrolysis of cellular inhibitors of nitric oxide synthase. Nat. Struct. Biol. (2001) 8 679-683.
77. MacAllister R., Parry H., Kimoto M. et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol. (1996) 119 1533-1540.
78. Leiper J., MacAllister R., Whitley G. et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology to microbial arginine deiminases. Biochem. J. (1999) 343 209-214.